💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Paroxetine Mesylate

CHEMBL1200609 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
425.5 g/mol
LogP
—
Phase
4

A mesylate salt form of paroxetine with the same therapeutic properties. This SSRI antidepressant treats depression, anxiety disorders, obsessive-compulsive disorder, and other mental health conditions.

分子量

425.5000 g/mol

TPSA

102.00 Ų

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Hepatitis C Prostate Cancer Colorectal Cancer

作用机制

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H20FNO3.CH4O3S/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;1-5(2,3)4/h1-6,9,14,17,21H,7-8,10-12H2;1H3,(H,2,3,4)/t14-,17-;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H24FNO6S

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
可旋转键数

                        
4

                    

                    
                    
                    

                        
重原子数

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
A mesylate salt form of paroxetine with the same therapeutic properties. This SSRI antidepressant treats depression, anxiety disorders, obsessive-compulsive disorder, and other mental health conditions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Paroxetine Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200609.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9845306.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.